ArticlePharmaceutical research2013
Drug delivery using platelet cancer cell interaction.
Article in Pharmaceutical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 99 citations in OpenAlex.
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- The future of brain tumor treatment: integrating platelet-based liquid biopsy, advanced drug delivery systems, and eicosanoid inhibition.Frontiers in pharmacology · 2026Review
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Potential of Platelet-Based Drug Delivery System for Treating Peritoneal Metastasis of Gastric Cancer.Cancer science · 2025Article
- Micro/Nano-Motors for Enhanced Tumor Diagnosis and Therapy.International journal of molecular sciences · 2025Review
- Better together: biomimetic nanomedicines for high performance tumor therapy.Beilstein journal of nanotechnology · 2025Review
- Review
- The shear rate promotes pinocytosis of extracellular dextran in platelets.Clinical hemorheology and microcirculation · 2024Article
- Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.Journal of biomedical science · 2023Review
- Platelets, Protean Cells with All-Around Functions and Multifaceted Pharmacological Applications.International journal of molecular sciences · 2023Review
- Magnetic Platelets as a Platform for Drug Delivery and Cell Trapping.Pharmaceutics · 2023Article
- New insights of platelet endocytosis and its implication for platelet function.Frontiers in cardiovascular medicine · 2023Review
- Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery.Drug delivery · 2022Article
- Cell-based carrier for targeted hitchhiking delivery.Drug delivery and translational research · 2022Review
- Antibiotic-Loaded Smart Platelet: A Highly Effective Invisible Mode of Killing Both Antibiotic-Sensitive and -Resistant Bacteria.ACS omega · 2022Article
- Platelets for cancer treatment and drug delivery.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Synthetic cells in biomedical applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies.Frontiers in pharmacology · 2022Review
- Biomimetic nanomaterial-facilitated oxygen generation strategies for enhancing tumour treatment outcomes.Frontiers in bioengineering and biotechnology · 2022Review
- Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop an efficient biocompatible and targeted drug delivery system in which platelets, an essential blood component having a natural affinity for cancer cells, are used as carrier of anticancer drug as delivery of drug to the targeted site is crucial for cancer treatment.
methodsDoxorubicin hydrochloride, a potent anti cancer drug, was delivered in lung adenocarcinoma cell line (A549) using platelet as a delivery agent. This delivery mode was also tested in Ehrlich ascites carcinoma (EAC) bearing mice in presence and absence of platelets.
resultsThe results show that platelets can uptake the drug and release the same upon activation. The efficiency of drug loaded platelets in inducing cytotoxicity was significantly higher in both in vitro and in vivo model, as compared to the free drug.
conclusionsThe proposed drug delivery strategy may lead to clinical improvement in the management of cancer treatment as lower drug concentration can be used in a targeted mode. Additionally the method can be personalized as patient's own platelet can be used for deliver various drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.